|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanthan R, Senger JL and Kanthan SC:
Molecular events in primary and metastatic colorectal carcinoma: A
review. Patholog Res Int. 2012:5974972012.PubMed/NCBI
|
|
3
|
Zheng ZX, Zheng RS, Zhang SW and Chen WQ:
Colorectal cancer incidence and mortality in China, 2010. Asian Pac
J Cancer Prev. 15:8455–8460. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fukushige S and Horii A: DNA methylation
in cancer: A gene silencing mechanism and the clinical potential of
its biomarkers. Tohoku J Exp Med. 229:173–185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Engeland M, Derks S, Smits KM, Meijer
GA and Herman JG: Colorectal cancer epigenetics: Complex
simplicity. J Clin Oncol. 29:1382–1391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakai E, Nakajima A and Kaneda A:
Accumulation of aberrant DNA methylation during colorectal cancer
development. World J Gastroenterol. 20:978–987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sipos F, Mũzes G, Patai AV, Fũri I,
Péterfia B, Hollósi P, Molnár B and Tulassay Z: Genome-wide
screening for understanding the role of DNA methylation in
colorectal cancer. Epigenomics. 5:569–581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Song BP, Jain S, Lin SY, Chen Q, Block TM,
Song W, Brenner DE and Su YH: Detection of hypermethylated vimentin
in urine of patients with colorectal cancer. J Mol Diagn.
14:112–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li W, Zhang X, Lu X, You L, Song Y, Luo Z,
Zhang J, Nie J, Zheng W, Xu D, et al: 5-Hydroxymethylcytosine
signatures in circulating cell-free DNA as diagnostic biomarkers
for human cancers. Cell Res. 27:1243–1257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schumacher A, Lichtarge O, Schwartz S and
Magnuson T: The murine Polycomb-group gene eed and its human
orthologue: Functional implications of evolutionary conservation.
Genomics. 54:79–88. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piunti A and Shilatifard A: Epigenetic
balance of gene expression by Polycomb and COMPASS families.
Science. 352:aad97802016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du J, Li L, Ou Z, Kong C, Zhang Y, Dong Z,
Zhu S, Jiang H, Shao Z, Huang B and Lu J: FOXC1, a target of
polycomb, inhibits metastasis of breast cancer cells. Breast Cancer
Res Treat. 131:65–73. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Scelfo A, Piunti A and Pasini D: The
controversial role of the Polycomb group proteins in transcription
and cancer: How much do we not understand Polycomb proteins? FEBS
J. 282:1703–1722. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu JI, Kang IH, Seo GS, Choi SC, Yun KJ
and Chae SC: Promoter polymorphism of the EED gene is associated
with the susceptibility to ulcerative colitis. Dig Dis Sci.
57:1537–1543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sriraksa R, Zeller C, Dai W, Siddiq A,
Walley AJ, Limpaiboon T and Brown R: Aberrant DNA methylation at
genes associated with a stem cell-like phenotype in
cholangiocarcinoma tumors. Cancer Prev Res (Phila). 6:1348–1355.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu YL, Gao X, Jiang Y, Zhang G, Sun ZC,
Cui BB and Yang YM: Expression and clinicopathological significance
of EED, SUZ12 and EZH2 mRNA in colorectal cancer. J Cancer Res Clin
Oncol. 141:661–669. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pike JG, Berardinucci G, Hamburger B and
Kiruluta G: The surgical management of urinary incontinence in
myelodysplastic children. J Pediatr Surg. 26:466–471. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen X, Yang Y, Liu J, Li B, Xu Y, Li C,
Xu Q, Liu G, Chen Y, Ying J and Duan S: NDRG4 hypermethylation is a
potential biomarker for diagnosis and prognosis of gastric cancer
in Chinese population. Oncotarget. 8:8105–8119. 2017.PubMed/NCBI
|
|
20
|
Chen R, Hong Q, Jiang J, Chen X, Jiang Z,
Wang J, Liu S, Duan S and Shi S: AGTR1 promoter hypermethylation in
lung squamous cell carcinoma but not in lung adenocarcinoma. Oncol
Lett. 14:4989–4994. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang Y, Chen X, Hu H, Jiang Y, Yu H, Dai
J, Mao Y and Duan S: Elevated UMOD methylation level in peripheral
blood is associated with gout risk. Sci Rep. 7:111962017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li B, Chen X, Jiang Y, Yang Y, Zhong J,
Zhou C, Hu H and Duan S: CCL2 promoter hypomethylation is
associated with gout risk in Chinese Han male population. Immunol
Lett. 190:15–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu H, Chen X, Wang C, Jiang Y, Li J, Ying
X, Yang Y, Li B, Zhou C, Zhong J, et al: The role of TFPI2
hypermethylation in the detection of gastric and colorectal cancer.
Oncotarget. 8:84054–84065. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang B, Du Z, Gao YT, Lou C, Zhang SG, Bai
T, Wang YJ and Song WQ: Methylation of Dickkopf-3 as a prognostic
factor in cirrhosis-related hepatocellular carcinoma. World J
Gastroenterol. 16:755–763. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khamas A, Ishikawa T, Shimokawa K, Mogushi
K, Iida S, Ishiguro M, Mizushima H, Tanaka H, Uetake H and Sugihara
K: Screening for epigenetically masked genes in colorectal cancer
Using 5-Aza-2′-deoxycytidine, microarray and gene expression
profile. Cancer Genomics Proteomics. 9:67–75. 2012.PubMed/NCBI
|
|
26
|
Shen Z, Chen X, Li Q, Zhou C, Xu Y, Yu R,
Ye H, Li J and Duan S: Elevated methylation of CMTM3 promoter in
the male laryngeal squamous cell carcinoma patients. Clin Biochem.
49:1278–1282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ji H, Wang Y, Liu G, Xu X, Dai D, Chen Z,
Zhou D, Zhou X, Han L, Li Y, et al: OPRK1 promoter hypermethylation
increases the risk of Alzheimer's disease. Neurosci Lett.
606:24–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Demokan S, Chuang AY, Pattani KM,
Sidransky D, Koch W and Califano JA: Validation of nucleolar
protein 4 as a novel methylated tumor suppressor gene in head and
neck cancer. Oncol Rep. 31:1014–1020. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park JY, Kim D, Yang M, Park HY, Lee SH,
Rincon M, Kreahling J, Plass C, Smiraglia DJ, Tockman MS and Kim
SJ: Gene silencing of SLC5A8 identified by genome-wide methylation
profiling in lung cancer. Lung Cancer. 79:198–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Margueron R and Reinberg D: The Polycomb
complex PRC2 and its mark in life. Nature. 469:343–349. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagarsheth N, Peng D, Kryczek I, Wu K, Li
W, Zhao E, Zhao L, Wei S, Frankel T, Vatan L, et al: PRC2
epigenetically silences Th1-Type chemokines to suppress effector
T-cell trafficking in colon cancer. Cancer Res. 76:275–282. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seo GS, Yu JI, Chae SC, Park WC, Shin SR,
Yoo ST, Choi SC and Lee SH: EED gene polymorphism in patients with
colorectal cancer. Int J Biol Markers. 28:274–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun D, Lin Y, Hong J, Chen H, Nagarsheth
N, Peng D, Wei S, Huang E, Fang J, Kryczek I and Zou W: Th22 cells
control colon tumorigenesis through STAT3 and polycomb repression
complex 2 signaling. Oncoimmunology. 5:e10827042016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Das PM and Singal R: DNA methylation and
cancer. J Clin Oncol. 22:4632–4642. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ravegnini G, Zolezzi Moraga JM, Maffei F,
Musti M, Zenesini C, Simeon V, Sammarini G, Festi D, Hrelia P and
Angelini S: Simultaneous analysis of SEPT9 promoter methylation
status, micronuclei frequency, and folate-related gene
polymorphisms: The potential for a novel blood-based colorectal
cancer biomarker. Int J Mol Sci. 16:28486–28497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kadiyska T and Nossikoff A: Stool DNA
methylation assays in colorectal cancer screening. World J
Gastroenterol. 21:10057–10061. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Y, Li D, Li X, Teng C, Zhu L, Cui B,
Zhao Y and Hu F: Prognostic significance of hMLH1/hMSH2 gene
mutations and hMLH1 promoter methylation in sporadic colorectal
cancer. Med Oncol. 31:392014. View Article : Google Scholar : PubMed/NCBI
|
